Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 4/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 3/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 5/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488163 | 0.93 | PIK3C2B (0.37) | PIK3C2BNR1H4DHODHNR1I2CYP1A2 | |
| SCHEMBL6501134 | 0.91 | BCL2 (0.47) | PIK3C2BDHODHBCL2MCL1PIK3CB | |
| SCHEMBL6502905 | 0.88 | PIK3C2B (0.41) | PIK3C2BDHODHBCL2MCL1PIK3CB | |
| SCHEMBL6487917 | 0.88 | PIK3C2B (0.39) | PIK3C2BDHODHBCL2MCL1AGTR1 | |
| SCHEMBL6501228 | 0.88 | BCL2 (0.40) | PIK3C2BDHODHBCL2MCL1ALOX5AP | |
| SCHEMBL6502827 | 0.87 | ALOX5AP (0.41) | PIK3C2BDHODHBCL2MCL1ALOX5AP | |
| SCHEMBL6500643 | 0.87 | ALOX5AP (0.40) | PIK3C2BDHODHBCL2MCL1ALOX5AP | |
| SCHEMBL6498787 | 0.85 | BCL2 (0.40) | PIK3C2BBCL2MCL1ALOX5APAGTR1 | |
| SCHEMBL6491148 | 0.85 | DCTPP1 (0.45) | DHODHBCL2MCL1ALOX5AP | |
| SCHEMBL6500738 | 0.85 | PIK3C2B (0.38) | PIK3C2BDHODHBCL2MCL1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PIK3C2B 2433/4885NR1H4 1441/4885DHODH 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.